-
Dr. Hanchong Toh: Promising Prospects for Immune Adjuvant Therapy in Liver Cancer
Liver cancer has become the 6th most common and the 3rd leading cause of cancer deaths worldwide. For liver cancer patients, surgery is the preferred method to completely eliminate tumors and achieve long-term survival. However, the majority of liver cancer patients still face late diagnoses and low survival rates. In recent years, the systemic treatment…
-
APPLE 2023 | Combining KRAS inhibitors may enhance immunotherapeutic response in liver cancer patients
Hepatocellular carcinoma (HCC) is the most common malignant liver tumor in our country, posing a significant threat to the lives and health of our people. Presently, the treatment for advanced HCC is primarily systemic therapy based on targeted and immunotherapy. Deciding on the appropriate multi-target inhibitors and immunotherapies for combined treatment is a hot topic…
-
Dr. Kathryn J. Fowler: When to Consider Biopsy – Radiologist’s Perspective
The diagnosis of liver cancer involves three aspects, including imaging, blood test results, and biopsy pathology results. Typically, the diagnosis of a tumor is confirmed only under a microscope after obtaining pathological tissue. However, liver cancer has its unique characteristics, and its diagnosis can be based on cirrhosis and confirmed through imaging tests such as…
-
Dr. Masatoshi Kudo: Does the Treatment Paradigm for Intermediate HCC Need to Change?
In recent years, there has been rapid progress in the systemic treatment of liver cancer, with new immunotherapies and targeted therapies continually emerging. This has also driven ongoing innovation in the concepts and approaches for treating HCC. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Experts Conference (APPLE 2023) was held…
-
Combined Radiotherapy, Anti-Angiogenic Medication, and Immunotherapy for Downstaging Treatment in Hepatocellular Carcinoma Complicated by Portal Vein
Hepatocellular carcinoma (HCC) is one of the most common malignancies in China, with most patients diagnosed in the intermediate to advanced stages. The formation of portal vein tumor thrombus (PVTT) is a critical indicator of HCC progression, and patients with HCC combined with PVTT have a very poor prognosis. Previous studies have shown that low-dose…
-
Dr. Wai-Kay Seto: Balancing the Risks and Benefits of Long-Term HBV Treatment
The World Health Organization (WHO) has set ambitious goals in its Action Plan for the Elimination of Viral Hepatitis: by 2030, the diagnosis rate for chronic hepatitis B (CHB) should reach 90%, the treatment rate for eligible patients should be 80%, new infections should decrease by 90%, and related deaths should decrease by 65%. However,…
-
Congratulations! Dr. Jian Zhou has been elected as the President-elect of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE)
From July 6th to 8th, 2023, the 13th annual meeting of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) was held in Seoul, South Korea, with the participation of nearly 1000 experts and scholars in the field of liver cancer from around the world. The current President and internationally renowned hepatopancreatobiliary surgeon, Dr. Norihiro Kokudo,…
-
Dr. Zhaochong Zeng: Enhancing Efficiency and Reducing Burden – Latest Advances in Radiotherapy for Liver Cancer Treatment
Stereotactic Body Radiotherapy (SBRT), as a novel radiotherapy technique, has achieved encouraging results in the treatment of liver cancer. It not only improves local tumor control but also reduces distant metastases caused by tumors. Additionally, it minimizes radiation therapy-related complications, enhancing the quality of life for patients after treatment. However, how to maximize the role…
Connecting Medical Expertise through Media